- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Geodon
Synonyms :
ziprasidone
Class :
2nd Generation, Antipsychotics
Dosage Forms & Strengths
capsule
80mg
60mg
40mg
20mg
For injection powder
20mg
Initially, 20 mg orally 2 times a day with meals; may be enhanced to every other day when necessary; should not exceed more than 80 mg every 12 hours.
Assess the need for maintaining on a regular basis; clinical research has shown that dosages exceeding 20 mg every 12 hours provide no further benefit.
(associated with acute agitation):
Intramuscular: 10 mg every 2 hours or 20 mg every 4 hours; no more than 40 mg daily; use Intramuscular for up to 3 days, then switch to orally if needed.
Acute treatment: 40 mg orally 2 times a day with meals initially; on day 2, increase to 60-80 mg orally 2 times a day if necessary; modify dose according to tolerability and efficacy within the range of 40-80 mg 2 times a day. Maintenance: Maintain at the same dosage at which the patient was first stabilised; review the necessary for maintenance therapy on a regular basis.
Dose Adjustments
Dosing Modifications Hepatic impairment: Use with caution; the drug is extensively metabolised in the liver, which might increase systemic exposure. Renal impairment: Adjusting the dose is not required with oral administration; caution is necessary with intramuscular administration.
Dosage Forms & Strengths
capsule
80mg
60mg
40mg
20mg
For injection powder
20mg
5 mg daily on days 1 to 3
Titrated to 40 mg daily divided every 12 hours from days 4 to28.
Refer to the adult dosing regimen
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may have an increased QTc-prolonging effect when combined with ziprasidone
It may enhance QTc interval when combined with perphenazine
QTc interval is increased both by lenvatinib and ziprasidone
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ziprasidone
when used together, entrectinib and ziprasidone both increase the QTc interval
when used together, encorafenib and ziprasidone both increase the QTc interval
ziprasidone and gilteritinib, when used in combination, increase the QTc interval
may increase the QTc interval when combined
it increases the toxicity of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may diminish the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined with ziprasidone
It may enhance sedation when combined with a shepherd's purse
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
may increase the risk of adverse effect of amphetamines
ziprasidone and mephenesin, when used together, the risk or seriousness of adverse events may rise
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
nabilone and ziprasidone, when used simultaneously, both increase the sedation
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the QTc interval
glycopyrrolate inhaled and formoterol
may diminish the effects through pharmacodynamic antagonism
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
eprosartan/hydrochlorothiazide
may increase the hypotensive effect of blood pressure-lowering agents
may increase the hypotensive effect of blood pressure-lowering agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased adverse effect when combined with antipsychotic agents
it increases the toxicity of antipsychotic agents
may increase the arrhythmogenic effect of Inhalational Anaesthetics
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increasingly adverse effect when combined with amphetamines
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may diminish the absorption when combined